| Neal Singh Athwal, | |
|
14 Mule Rd Ste 1, Toms River, NJ 08755-5060 | |
| (732) 286-0900 | |
| Not Available |
| Full Name | Neal Singh Athwal |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 7 Years |
| Location | 14 Mule Rd Ste 1, Toms River, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295222511 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 27OA00679000 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ravine Eye Center Inc | 2860405479 | 3 |
| Shore Eye Associates Pa | 9133195126 | 17 |
News Archive
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
Vasoproliferative ocular diseases are responsible for sight loss in millions of people in the industrialised countries. Many patients do not currently respond to the treatment offered, which targets a specific factor, VEGF. A team of Inserm researchers at the Vision Institute (Inserm/CNRS/Pierre and Marie Curie University), in association with a team from the Yale Cardiovascular Research Center, have demonstrated in an animal model that blocking another protein, Slit2, prevents the pathological blood vessel development that causes these diseases.
Could looking at the eyes provide a new way of studying how anesthesia affects the developing brain? The retinas of immature mice exposed to one widely used general anesthetic show evidence of "programmed cell death," or apoptosis, reports a study in Anesthesia & Analgesia.
"A $112 million settlement involving alleged drug kickbacks that the Justice Dept. announced with the nation's largest nursing home pharmacy and a generic drug manufacturer on Nov. 3 is part of a wide-ranging investigation of suspected Medicaid fraud by the pharmaceutical industry," Business Week reports. "Critics say the continuing probe, which involves Johnson & Johnson (JNJ) and other major drugmakers, highlights what they describe as an industry practice of paying money to outfits that provide drugs to consumers, in return for preferential treatment."
› Verified 8 days ago
| Provider Name | Athwal Eye Associates, P.c |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1659433142 PECOS PAC ID: 6002801891 Enrollment ID: O20040420000457 |
News Archive
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
Vasoproliferative ocular diseases are responsible for sight loss in millions of people in the industrialised countries. Many patients do not currently respond to the treatment offered, which targets a specific factor, VEGF. A team of Inserm researchers at the Vision Institute (Inserm/CNRS/Pierre and Marie Curie University), in association with a team from the Yale Cardiovascular Research Center, have demonstrated in an animal model that blocking another protein, Slit2, prevents the pathological blood vessel development that causes these diseases.
Could looking at the eyes provide a new way of studying how anesthesia affects the developing brain? The retinas of immature mice exposed to one widely used general anesthetic show evidence of "programmed cell death," or apoptosis, reports a study in Anesthesia & Analgesia.
"A $112 million settlement involving alleged drug kickbacks that the Justice Dept. announced with the nation's largest nursing home pharmacy and a generic drug manufacturer on Nov. 3 is part of a wide-ranging investigation of suspected Medicaid fraud by the pharmaceutical industry," Business Week reports. "Critics say the continuing probe, which involves Johnson & Johnson (JNJ) and other major drugmakers, highlights what they describe as an industry practice of paying money to outfits that provide drugs to consumers, in return for preferential treatment."
› Verified 8 days ago
| Provider Name | Shore Eye Associates Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093737017 PECOS PAC ID: 9133195126 Enrollment ID: O20040910000056 |
News Archive
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
Vasoproliferative ocular diseases are responsible for sight loss in millions of people in the industrialised countries. Many patients do not currently respond to the treatment offered, which targets a specific factor, VEGF. A team of Inserm researchers at the Vision Institute (Inserm/CNRS/Pierre and Marie Curie University), in association with a team from the Yale Cardiovascular Research Center, have demonstrated in an animal model that blocking another protein, Slit2, prevents the pathological blood vessel development that causes these diseases.
Could looking at the eyes provide a new way of studying how anesthesia affects the developing brain? The retinas of immature mice exposed to one widely used general anesthetic show evidence of "programmed cell death," or apoptosis, reports a study in Anesthesia & Analgesia.
"A $112 million settlement involving alleged drug kickbacks that the Justice Dept. announced with the nation's largest nursing home pharmacy and a generic drug manufacturer on Nov. 3 is part of a wide-ranging investigation of suspected Medicaid fraud by the pharmaceutical industry," Business Week reports. "Critics say the continuing probe, which involves Johnson & Johnson (JNJ) and other major drugmakers, highlights what they describe as an industry practice of paying money to outfits that provide drugs to consumers, in return for preferential treatment."
› Verified 8 days ago
| Provider Name | Ravine Eye Center Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1700839743 PECOS PAC ID: 2860405479 Enrollment ID: O20060727000336 |
News Archive
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
Vasoproliferative ocular diseases are responsible for sight loss in millions of people in the industrialised countries. Many patients do not currently respond to the treatment offered, which targets a specific factor, VEGF. A team of Inserm researchers at the Vision Institute (Inserm/CNRS/Pierre and Marie Curie University), in association with a team from the Yale Cardiovascular Research Center, have demonstrated in an animal model that blocking another protein, Slit2, prevents the pathological blood vessel development that causes these diseases.
Could looking at the eyes provide a new way of studying how anesthesia affects the developing brain? The retinas of immature mice exposed to one widely used general anesthetic show evidence of "programmed cell death," or apoptosis, reports a study in Anesthesia & Analgesia.
"A $112 million settlement involving alleged drug kickbacks that the Justice Dept. announced with the nation's largest nursing home pharmacy and a generic drug manufacturer on Nov. 3 is part of a wide-ranging investigation of suspected Medicaid fraud by the pharmaceutical industry," Business Week reports. "Critics say the continuing probe, which involves Johnson & Johnson (JNJ) and other major drugmakers, highlights what they describe as an industry practice of paying money to outfits that provide drugs to consumers, in return for preferential treatment."
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Neal Singh Athwal, 5 Cranmoor Dr, Toms River, NJ 08753-6803 Ph: (732) 580-5965 | Neal Singh Athwal, 14 Mule Rd Ste 1, Toms River, NJ 08755-5060 Ph: (732) 286-0900 |
News Archive
Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).
Vasoproliferative ocular diseases are responsible for sight loss in millions of people in the industrialised countries. Many patients do not currently respond to the treatment offered, which targets a specific factor, VEGF. A team of Inserm researchers at the Vision Institute (Inserm/CNRS/Pierre and Marie Curie University), in association with a team from the Yale Cardiovascular Research Center, have demonstrated in an animal model that blocking another protein, Slit2, prevents the pathological blood vessel development that causes these diseases.
Could looking at the eyes provide a new way of studying how anesthesia affects the developing brain? The retinas of immature mice exposed to one widely used general anesthetic show evidence of "programmed cell death," or apoptosis, reports a study in Anesthesia & Analgesia.
"A $112 million settlement involving alleged drug kickbacks that the Justice Dept. announced with the nation's largest nursing home pharmacy and a generic drug manufacturer on Nov. 3 is part of a wide-ranging investigation of suspected Medicaid fraud by the pharmaceutical industry," Business Week reports. "Critics say the continuing probe, which involves Johnson & Johnson (JNJ) and other major drugmakers, highlights what they describe as an industry practice of paying money to outfits that provide drugs to consumers, in return for preferential treatment."
› Verified 8 days ago
Dr. Randy S Nissinoff, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1278 Hooper Ave, Toms River, NJ 08753 Phone: 732-505-0533 Fax: 732-505-6572 | |
Dr. Jack Robert Schwartz, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1341 Highway 9 Ste 10, Toms River, NJ 08755 Phone: 732-240-9111 Fax: 732-286-1405 | |
Dr. Nicole Mary Caldeira-flanagan, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 20 Mule Rd, Toms River, NJ 08755 Phone: 732-349-5622 Fax: 732-349-5625 | |
Dr. John Emmanuel Komis Ackep, OD Optometrist Medicare: Medicare Enrolled Practice Location: 864 Route 37 W, 5723, Toms River, NJ 08755 Phone: 732-341-7433 | |
Dr. Aaron L Stefan, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 413 Lakehurst Rd, Bldg 1, Toms River, NJ 08755 Phone: 732-244-4322 Fax: 732-244-4320 | |
David M. Talbot, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1201 Hooper Ave, Ocean County Mall Space 1045-46, Toms River, NJ 08753 Phone: 732-240-2077 | |
Dr. Ivy Hopp Spears, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 40 Bey Lea Rd, Bey Lea Commons Suite C 104, Toms River, NJ 08753 Phone: 732-341-1070 Fax: 732-341-1652 |